Bloomage BioTechnology (688363) Fundamentals 2026 — P/E 72.0x, Revenue Analysis | SniperIQ
Bloomage BioTechnology (688363) is a CN-listed Basic Materials company in Chemicals - Specialty with a market capitalization of ¥7.5B, trading at ¥38.80 on the SHH. This SniperIQ fundamentals page covers Bloomage BioTechnology's valuation (P/E 72.0x, P/B 2.5x), profitability (net margin 6.5%), revenue (¥4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bloomage BioTechnology's market cap?
Bloomage BioTechnology (688363) has a market capitalization of approximately ¥7.5B, trading at ¥38.80 on the SHH. Market cap moves with the live share price.
What is Bloomage BioTechnology's P/E ratio?
Bloomage BioTechnology's trailing twelve-month P/E ratio is 72.0x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is Bloomage BioTechnology?
Bloomage BioTechnology runs a net profit margin of 6.5%, a gross margin of 68.2%, and an operating margin of 6.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bloomage BioTechnology generate?
Bloomage BioTechnology reported revenue of ¥4.2B for fiscal year 2025, with net income of ¥292M and earnings per share (EPS) of 0.61. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bloomage BioTechnology pay a dividend?
Bloomage BioTechnology offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bloomage BioTechnology financially healthy?
Bloomage BioTechnology carries a debt-to-equity ratio of 0.04x and a current ratio of 2.36x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bloomage BioTechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bloomage BioTechnology (688363) the key facts are: market cap ¥7.5B, P/E 72.0x, revenue ¥4.2B, 52-week range 32.92-61.85. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track Bloomage BioTechnology's full fundamentals live
Get Bloomage BioTechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.